A recent Bloomberg Law article reports on an upcoming court ruling for the case Alliance for Hippocratic Medicine v. FDA, which will decide whether to halt production of mifepristone, an abortion pill. Professor Wendy Parmet, director of Northeastern University’s Center for Health Policy and Law, is quoted in the article. She asserts that “This would be an injunction that really changes the status quo. It’s a pretty momentous thing to take the medication off the market that had been on the market for 20 years.”This ruling will have significant implications for medical abortions in the United States— mifepristone is the most common form of abortion care, and its injunction would leave only two options, a misoprostol-only regimen, or surgical abortion. Attorneys note that if the judge rules to immediately remove the drug from the marketplace, the case could its way to the Supreme Court.
This would be an injunction that really changes the status quo. It’s a pretty momentous thing to take the medication off the market that had been on the market for 20 years.Wendy Parmet, Northeastern University Center for Health Policy and Law
Read more on the potential implications for the ruling at Bloomberg Law.
Image credits: Bloomberg Law